NovoCure Ltd.
370 articles about NovoCure Ltd.
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
1/9/2023
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022.
-
NovoCure's novel cancer-fighting platform hits the mark in non-small cell lung cancer.
-
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
1/5/2023
Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone.
-
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
12/27/2022
Novocure announced it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023.
-
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
11/29/2022
Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM).
-
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
11/23/2022
Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.
-
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
11/17/2022
Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa.
-
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
11/15/2022
Novocure announced it has opened a new office in Montreal to expand and support its growing business in Canada.
-
Novocure Secures CE Mark for New Array
11/11/2022
Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma.
-
Novocure Reports Third Quarter 2022 Financial Results
10/27/2022
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022.
-
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
10/21/2022
Novocure announced 11 poster presentations on Tumor Treating Fields will be featured at the American Society for Radiation Oncology 2022 Annual Meeting from Oct. 23 to Oct. 26 in San Antonio, Texas.
-
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
10/20/2022
Novocure announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment.
-
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
10/20/2022
Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).
-
Novocure to Report Third Quarter 2022 Financial Results
10/3/2022
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.
-
NovoCure announced the launching of a U.S.-based arm to focus on and attempt to grow its glioblastoma (GBM) business and increase its patient population.
-
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
9/21/2022
Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise.
-
Novocure to Participate in Upcoming Investor Conferences in September 2022
8/31/2022
Novocure announced that management will participate in two upcoming investor conferences.
-
Novocure Reports Second Quarter 2022 Financial Results
7/28/2022
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022.
-
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
7/27/2022
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
-
Novocure to Report Second Quarter 2022 Financial Results
7/1/2022
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.